Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Xencor's XmAb5871 shows encouraging results in mid-stage study in IgG4-RD
Published Nov 13, 2016 09:21PM ET
Xencor's XmAb5871 shows encouraging results in mid-stage study in IgG4-RD
- Preliminary results from an open-label pilot Phase 2 study assessing Xencor's (NASDAQ:XNCR) lead product candidate XmAb5871 in patients with active IgG4-related disease (IgG4-RD) showed a positive treatment effect in most patients. The data were presented at the American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting in Washington, D.C.
- Nine of 11 of patients who received an initial intravenous (IV) dose of XmAb5871 achieved a response within two weeks which generally deepened over time. Responses are measured by a scale called IgG4-RD Responder Index.
- XmAb5871 is being administered every other week. No serious adverse events (AEs) have been reported. Treatment-related AEs (TRAEs) have occurred in five patients. TRAEs occurring in more the one patient were abdominal pain/discomfort (n=3) and mild headache (n=2). There was one discontinuation due to a moderate hypersensitivity reaction following the fifth infusion which resolved without medical management. The subject was later found to have developed anti-drug antibodies.
- Two other subjects discontinued prior to receiving all 12 planned infusions. One had an initial response to therapy that was lost and one failed to respond at all.
- XmAb5871 is a monoclonal antibody that targets CD19, specifically TcyRIIb, a receptor that inhibits B cell function without killing the cells. Inhibiting the function of B cells is a proven approach to treating many autoimmune diseases.
- IgG4-RD is an autoimmune disorder characterized by chronic inflammation, specifically tissue infiltration with lymphocytes (includes B cells) and IgG-4-secreting plasma cells. It is a relapsing-remitting condition associated with varying degrees of fibrosis. It can lead to organ failure if untreated, although it usually responds well to oral steroids. The specific prevalence is unknown but it is rare, occurring in 2.8 - 10.8/million according to one study conducted in Japan.
- Complete results should be available in 2017.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.